Protocol optimization of the quantification of gait using the GAITRite in m.3243A>G carriers

Published: 28-01-2016 Last updated: 20-04-2024

Protocol optimization for the GAITRite in m.3243A>G carriers

Ethical review Approved WMO

Status Recruitment stopped

Health condition type Metabolic and nutritional disorders congenital

Study type Observational non invasive

Summary

ID

NL-OMON42798

Source

ToetsingOnline

Brief title

GAITRite in m.3243A>G

Condition

Metabolic and nutritional disorders congenital

Synonym

disturbance in energy metabolism, mitochondrial disease

Research involving

Human

Sponsors and support

Primary sponsor: Universitair Medisch Centrum

Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: gait, GAITRite, m.3243A>G, mitochondrial disease, outcome measure

Outcome measures

Primary outcome

The paramaters calculated by the GAITRite

Secondary outcome

Muscle power mm. quadriceps

3 min walking test

Berg Balance Scale

Balance (forceplatform)

Study description

Background summary

There is a quest for sensitive outcome measures for clinical trials in m.3243A>G carriers, the most frequent mutation of mtDNA.

Gait abnormalities are frequently reported by patients carrying the m.3243A>G mutation.

Tthe group from Newcastle reported abnormal gait in a small cohort of m.3243A>G carriers using the GAITRite

Study objective

Protocol optimization for the GAITRite in m.3243A>G carriers

Study design

Observational study with non invasive measurements testing 3 different protocols and their test-retest reliability and deviation from healthy controls

Study burden and risks

Limited burden

2 - Protocol optimization of the quantification of gait using the GAITRite in m.3243 ... 25-05-2025

No risk

Large grouprelatedness since this study is a preparation for the phase 2 trial in this population.

Contacts

Public

Selecteer

Geert grooteplein noord 10 Nijmegen 6500 HB NL

Scientific

Selecteer

Geert grooteplein noord 10 Nijmegen 6500 HB NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

Carrier of the m.3243A>G mutation Older than 18 years; Healthy = no conditions leading to abnormal gait (orthopedic, neurological or neuromuscular disorders)

Exclusion criteria

Orthopedic problems interfering with gait Not able to walk for 3 minutes

Study design

Design

Study type: Observational non invasive

Intervention model: Other

Allocation: Non-randomized controlled trial

Masking: Open (masking not used)

Control: Active Primary purpose: Other

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 01-02-2016

Enrollment: 100

Type: Actual

Ethics review

Approved WMO

Date: 28-01-2016

Application type: First submission

Review commission: CMO regio Arnhem-Nijmegen (Nijmegen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

CCMO NL56121.091.15